Cargando…

Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens

OBJECTIVE: Monoclonal antibodies (MAbs) directed against the CD20 and CD52 antigens are used increasingly in patients with multiple sclerosis (MS). Several life-threatening opportunistic infections have been reported in postmarketing case series. The aim of this study was to investigate the incidenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zappulo, Emanuela, Buonomo, Antonio Riccardo, Saccà, Francesco, Russo, Cinzia Valeria, Scotto, Riccardo, Scalia, Giulia, Nozzolillo, Agostino, Lanzillo, Roberta, Tosone, Grazia, Gentile, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837838/ https://www.ncbi.nlm.nih.gov/pubmed/31723572 http://dx.doi.org/10.1093/ofid/ofz445

Ejemplares similares

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak
por: Buonomo, Antonio, et al.
Publicado: (2020)

The role of curcumin in liver diseases
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2018)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?
por: Nardelli, Carmela, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
por: Capasso, Nicola, et al.
Publicado: (2020)

Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the iceberg
por: Capasso, Nicola, et al.
Publicado: (2021)

Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience
por: Gentile, Ivan, et al.
Publicado: (2021)

COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy)
por: Gentile, Ivan, et al.
Publicado: (2022)

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19
por: Scotto, Riccardo, et al.
Publicado: (2022)

Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2021)

Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2022)

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2020)

Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2022)

Update on the Management of Surgical Site Infections
por: Pinchera, Biagio, et al.
Publicado: (2022)

Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
por: Maraolo, Alberto Enrico, et al.
Publicado: (2022)

Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2019)

Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma
por: Capoluongo, Ettore, et al.
Publicado: (2021)

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018)

Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
por: Kasarello, Kaja, et al.
Publicado: (2021)

CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm(3) Versus Universal Eligibility for Antiretroviral Therapy
por: Schooley, Alan L., et al.
Publicado: (2016)

Moderate to Intense Physical Activity Is Associated With Improved Clinical, CD4/CD8 Ratio, and Immune Activation Status in HIV-Infected Patients on ART
por: Bernal, Enrique, et al.
Publicado: (2021)

CD52+ regulatory T cells and CD52-expressing sperms downregulated in couples with unexplained infertility: A case–control study
Publicado: (2020)

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
por: Moccia, Marcello, et al.
Publicado: (2020)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
por: Besteman, Sjanna B, et al.
Publicado: (2022)

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
por: Scotto, Riccardo, et al.
Publicado: (2023)

Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects
por: Mondatore, Debora, et al.
Publicado: (2022)

The Impact of Human Pegivirus on CD4 Cell Count in HIV-Positive Persons in Botswana
por: N’Guessan, Kombo F, et al.
Publicado: (2017)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Efficient HIV-1 Trans Infection of CD4(+) T Cells Occurs in the Presence of Antiretroviral Therapy
por: Rappocciolo, Giovanna, et al.
Publicado: (2019)

Diabetes and COVID-19: The potential role of mTOR
por: Pinchera, B., et al.
Publicado: (2022)

Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia
por: Scotto, Riccardo, et al.
Publicado: (2021)

Engineering an anti-CD52 antibody for enhanced deamidation stability
por: Qiu, Huawei, et al.
Publicado: (2019)

Stable HIV Reservoir Despite Prolonged Low-Dose Mycophenolate to Limit CD4+ T-cell Proliferation
por: Schiffer, Joshua T, et al.
Publicado: (2022)

The Sympathetic Nervous System Is Necessary for Development of CD4(+) T-Cell Memory Following Staphylococcus aureus Infection
por: Reel, Jessica M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vd34jd3ffknmvgiuv603t30sfr